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ABSTRACT    
 
     BACKGROUND: HAART has improved survival of HIV patients. 
Its contribution to the development of new cardiovascular 
abnormalities has generated much interest. This study aimed at 
determining the prevalence of QTc prolongation among HIV 
patients and determining the influence if any of the use of HAART 
on the QTc and on the risk of having QTc prolongation. 
MATERIALS AND METHODS: One hundred and fifty HIV 
positive subjects comprising 76 HIV positive subjects on HAART 
(Group A), 74 who were HAART- naïve (Group B), and 150 age 
and sex-matched healthy controls (Group C) were studied. All 
subjects had electrocardiography, and QTc duration was 
calculated. 
RESULTS: Mean QTc was significantly different among the three 
groups (P <0.001), highest in Group B > Group A > Group C. 
Frequency of QTc prolongation was highest in Group B (32%)>, 
Group A (17.3%)> Group C (4.7%) (P<0.001). Mean QTc was 
significantly longer among patients with CD4 count <200 
cells/mm
3
 than among those with >200 cells/mm
3
 0.445 + 0.03secs 
vs 0.421 + 0.03secs (P<0.001).  QTc prolongation was commoner 
among individuals with CD4 count <200 cells/mm
3
 50% vs 20.5% 
(P<0.001). On binary logistic regression, none of the HAART 
medications used by our patients was predictive of the occurrence 
of QTc prolongation. 
CONCLUSION: The QTc is longer, and QTc prolongation occurs 
more frequently in HAART-naïve HIV patients than patients on 
HAART and healthy controls. None of the HAART medications 
used by our patients was predictive of the development of QTc 
prolongation. 
KEYWORDS: QTc prolongation, HIV/AIDS, Highly Active Anti-




The Human Immunodeficiency Virus (HIV)/Acquired Immune 
Deficiency Syndrome (AIDS) pandemic is one of the most 
significant public health problems of the last four decades. Current 
concepts of its management have broadened from initial emphasis on 
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opportunistic infections to the management of 
other organ-related complications (1,2). This is 
because the introduction of the Highly Active 
Anti-Retroviral Therapy (HAART) has 
significantly improved the survival of HIV 
patients and enabled them to live long enough to 
develop other systemic complications of the 
disease (3). Cardiovascular involvement in 
HIV/AIDS was recognized in the early days of the 
pandemic (4) and a wide spectrum of 
cardiovascular abnormalities (5-9) including 
electrocardiographic abnormalities such as 
corrected QT interval (QTc) prolongation (10-12) 
have been reported.  
The influence of HAART on the occurrence 
of QTc prolongation has also generated much 
interest with concerns that while contributing 
significantly to increased patient survival, 
HAART also increases patients’ risk for 
cardiovascular diseases such as life-threatening 
arrhythmias, myocardial infarction and sudden 
cardiac death (13,14).   It is therefore important to 
assess important electrocardiographic parameters 
such as the QTc in HIV/AIDS patient on HAART 
in order to have a comprehensive understanding of 
their risk for cardiovascular events and to provide 
a rational basis for actions that will reduce the 
occurrence of cardiovascular morbidity and 
mortality. The objectives of this study were to  
determine the prevalence of QTc prolongation  
among HIV positive patients and   to determine 
the influence if any of the use of HAART on the 
QTc and on the risk of having QTc prolongation. 
 
MATERIALS AND METHODS 
 
The study was a cross-sectional study carried out 
in the HIV clinics of the University of Ilorin 
Teaching Hospital (UITH), Ilorin, North central 
Nigeria. UITH is a large 500-bed tertiary 
healthcare facility whose HIV treatment service 
units receive referrals from about 5 neighbouring 
states of the federation. 
Study population: The participants were HIV 
positive patients attending the HIV clinics of 
UITH and  healthy age and sex-matched 
apparently healthy control subjects. The control 
subjects were recruited from among HIV negative 
blood donors in the UITH blood bank, volunteers 
from the Hospital and the surrounding community 
provided they satisfied the inclusion and exclusion 
criteria. 
Inclusion criteria: Consenting  HIV positive 
patients >18 years of age with confirmed HIV 
positive results based on serological rapid tests 
done in UITH. The patients were receiving 
treatment in the HIV clinics of UITH.   
Exclusion criteria: Patients with pre-existing 
systemic hypertension or other cardiac disease, 
arrhythmias or other conduction abnormalities, 
diabetes mellitus, or who were currently pregnant 
or in pueperium were excluded from the study. 
Patients with a history of current use of drugs 
known to affect the cardiovascular system or 
cause QTc prolongation or other drugs apart from 
antiretroviral drugs, as well as those with alcohol 
intake, cigarette smoking and electrolyte 
abnormalities were also excluded from the study. 
Sample size calculation/sampling technique: 
The minimum sample size was calculated using 
the Fisher’s statistical formula for estimating 
minimum sample size in health studies (15). The 
regional HIV prevalence rate of the study area 
which was 5.7%  at the start of the study, and 95% 
confidence  level, degree of accuracy of 0.05 and 
attrition rate of 10% were used in the calculation. 
The minimum sample size for the study was 82. 
Hence, 164 HIV positive subjects were enrolled 
consecutively into the study and divided into two 
groups of 82 HIV positive subjects each: Group A 
comprising 82 patients already on HAART and 
Group B comprising 82 HIV positive subjects who 
were HAART-naïve. However, 14 of them fell 
short of the inclusion criteria. Thus, 150 HIV 
positive subjects comprising 76 HIV positive 
subjects on HAART and 74 who were HAART- 
naïve were enrolled in to the study. One hundred 
and fifty age and sex-matched apparently healthy 
control subjects were also recruited from among 
HIV negative blood donors in the UITH blood 
bank, volunteers in the Hospital and in the 
surrounding community. 
Study protocol: The presence of HIV infection in 
the patients was determined by a positive ELISA 
antibody test and Western blot confirmation. 
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When Western blot was not available, diagnosis 
was based on two positive ELISA antibody tests 
using different kits and existence of at least two 
major and one minor signs of the disease in the 
absence of any known cause of 
immunosuppression. The CD4+ T lymphocyte cell 
count was measured by flow cytometry method 
using the DYNAL® T4 QUANT KIT, (made by 
DYNA Biotech, Oslo, Norway). 
Electrocardiogram (ECG) recording was done 
on all study subjects using a Schiller® Cardiovit 
AT-10  ECG machine (SCHILLER AG Altgasse, 
Switzerland) operating at a speed of 25mm/second 
and sensitivity of 10mm/mv in accordance with 
the recommendations of the American Heart 
Association (AHA) on the standardization of leads 
and specification of instrument (16). Recordings 
were made after the individuals had rested for 
between 10-15 minutes and were interpreted by  
two different cardiologists among the authors. 
Lead II was used as the rhythm strip. The QT 
interval was measured in Lead II from the 
beginning of the QRS complex to the end of the T 
wave downslope. In the presence of a U wave 
which joined the T wave, the QT interval was 
measured from the beginning of the QRS complex 
to the lowest point of the curve between the T and 
U waves. The QT interval was then corrected for 
heart rate using Bazett’s formula (17). The upper 
limits of normal was set at 440ms for men and 
460ms for women (18,19). Clinical examination 
was carried out on all participants, and their age, 
sex, body mass index (BMI), blood pressure (BP), 
ECG heart rate (HR) and QTc were recorded. For 
HIV positive patients, the duration of HIV 
diagnosis, CD4 count, HAART medications used 
and duration of HAART use were also recorded. 
HIV viral load assay was not done for the patients 
because of non-availability of the facility at the 
study location.  
Statistical analysis: The Statistical Package for 
the Social Sciences version 20 (SPSS inc., 
Chicago, IL, USA) was used to perform the 
statistical analysis. Continuous variables were 
expressed as mean ± standard deviation. 
Categorical variables were expressed as 
percentages. Chi square was used to test 
significant differences between proportions and 
the independent t-test was used to compare means 
of two groups while one-way analysis of variance 
(ANOVA) was used to compare the means of 
three groups. Multiple pairwise comparisons 
between the groups were then performed using the 
Tukey test for post hoc analysis to determine 
where the significant difference impliedby 
ANOVA truly lies. Statistical significance was set 
at P < 0.05. Binary logistic regression models 
were also generated to examine the relationship 
between the use of the various HAART 
medications and the occurrence or otherwise of 
prolonged QTc. “Prolonged QTc” was the 
dependent variable measured on a dichotomous 
scale “present” or “absent”, and the different 
individual anti-retroviral medications were set as 
independent variables. 
Ethical approval: Ethical approval was obtained 
from the Ethical Review Board of the University 
of Ilorin Teaching Hospital, Ilorin, Nigeria. All 
procedures followed were in accordance with the 
ethical standards of the responsible committee on 
human experimentation (institutional or regional) 
or with the Helsinki Declaration of the 1975, as 




The 150 HIV positive patients in the study 
consisted of 64 males (42.7%), and 86 females 
(57.3%) were recruited consecutively for this 
study. The 76 Group A patients who were already 
on HAART comprised 32 males and 44 females 
while the seventy-four Group B patients 
comprised  31 males and  43 females. The age and 
sex- matched 150 apparently healthy HIV negative 
controls comprised  63 males and 87 females 
(Group C). The mean ages of the three groups of 
subjects were statistically similar Group A- 38.7+ 
8.8, Group B – 35.8+ 8.2 and Group C - 40.1+ 
16.9 (P=0.083). The mean BMI was significantly 
different among the 3 groups (P<0.001). Multiple 
pairwise comparisons showed that it was higher in 
Group C than in among Group A and also higher 
in Group C than in Group B subjects. The BMI 
was similar between both groups of HIV patients. 
The systolic BP was also significantly different 
among the three groups (P=0.011), it was higher 
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among healthy controls (Group C) than Group B 
but similar between Groups A and B and between 
Groups B and C subjects. The mean QTc was 
significantly different among the three groups (P 
<0.001); it was highest in Group B followed by 
Group A than Group C. Pairwise comparisons also 
revealed significant differences in all pairs of the 
Groups. The frequency of QTc prolongation was 
significantly different across the three groups; it 
was the highest in Group B (32%), then Group A 
(17.3%) and the lowest among healthy controls of 
Group C (4.7%). 
TABLE 1: Physical and Electrocardiographic Characteristics of Study Participants 
 
 

















Age (years) 38.7+ 8.8 35.8 + 8.2 40.1+ 16.9 0.083 - 
Gender 
Male, n (%) 
















)      21.7 +4.9          20.8 + 5.2 25.1 + 4.7 < 0.001* C>A; C>B 
Heart rate (beats/min) 85.1 + 17.5 100.5 + 23.2 82.9 + 19.6 <0.001* B>A>C 
Systolic BP (mmHg) 113.9 +13.1 110.5 + 12.1 115.3 + 9.4 0.011* C>B 
Diastolic BP (mmHg) 73.9 + 8.9 73+ 9.1 74.1 + 7.7 0.653 - 
QTc (mean +SD)     0.424+0.03 0.442+ 0.03 0.421+0.04
 .04 
<0.001* B>A>C 
Prolonged QTc (%) 17.3 32 4.7 <0.001* B>A>C 
HIV- Human Immunodeficiency Virus,  BMI- Body Mass Index, BP- Blood pressure. Except otherwise stated, values 
are mean+ standard deviation. *Significant 
 
Gender comparisons among the HIV patients revealed 
that the QTc duration was significantly longer among 
male HIV patients on HAART than male HAART-
naïve patients, but similar among female patients in 
both groups of HIV positive patients. The mean QTc 
was, however, similar among female HIV patients 
(Table 2). The mean QTc was also significantly longer 
among patients with CD4 count <200 cells/mm
3
 than 
among those with CD4 count >200 cells/mm
3
 0.445 + 
0.03secs vs 0.421 + 0.03secs (P<0.001).  When the 
patients were classified according to the degree of 
immunosuppression into those with current CD4 count 
<200 cells/mm
3
 (72 patients) and those with CD4 count 
>200 cells/mm
3 
(78 patients), 50% of the individuals 
with CD4 count <200 cells/mm
3
 had QTc prolongation 
while, among individuals with CD4 count >200 
cells/mm
3
, only 20.5% had QTc prolongation  
(P<0.001). 
 
Table 2: QTc and CD4 Count of Hiv Patients. 
 
 Group A : HIV +ve on 
HAART  
N=76 








0.417 + 0.03 
0.430 + 0.03 
 
0.442 + 0.04 




CD4  Count (cells/mm
3
) 383.4 + 23.8 252.7 + 23.5 0.045* 
Except otherwise stated, values are mean+ standard deviation *Significant 
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Table 3: Comparison of Qtc Duration between Patients with CD4 Count <200 Cells/Mm
3
 and Those with 
CD4 Count >200 Cells/Mm
3 
 









QTc Duration (sec) 0.445 + 0.03  0.421 + 0.03 <0.001* 
QTc Prolongation (%) 50 20.5 <0.001* 
Except otherwise stated, values are mean+ standard deviation  *Significant  
 
Binary logistic regression was performed to 
ascertain the effects of HAART medications on 
the likelihood that patients develop prolonged 
QTc. The logistic regression model fitted well at 
χ
2 
(7) = 7.978. The model correctly classified  
83.3% of cases and explained only 12.2% 
(Nagelkerke R
2
) of the variance in QTc 
prolongation due to individual HAART 
medication. None of the Nucleotide Reverse 
Transcriptase Inhibitors on Non-Nucleotide 
Reverse Transcriptase Inhibitors (NNRTI) 
analysed in the model was predictive of the 
development of QTc prolongation as the outcome 
variable (Table 4). There were only two patients 
on PI, and these were automatically excluded from 
the model since the number was too few to make 
meaningful impact on the model. 
 
Table 4: Prediction of the Development of Prolonged Qtc in HIV Patients by the Use of HAART 
Medications  
 
 B Odds Ratio 95% CI P value 
Nevirapine .117 1.125 0.040 - 31.906 0.945 
Efavirenz -1.936 .144 0.004- 4.667 0.275 
Lamivudine 17.658 4.66 0.005- 6.004. 1.000 
Stavudine -.066 .936 0.096 - 9.113 0.954 
Tenofovir 19.384 2.62 0.008- 4.009 1.000 
Emtricitabine -0.672 0.511 0.113 -  2.303 0.382 
Zidovudine -0.161 0.851 0.088 – 8.272 0.889 




The QTc is an electrocardiographic indicator of the 
duration of action potential in the ventricles 
representing the sum total of ventricular depolarization 
and repolarization. Its prolongation is indicative of 
increased risk of potentially fatal arrhythmias. 
Ventricular action potential is caused by the flow of 
ions across the myocyte cell membrane in two major 
currents which are: (1)   the Inward depolarizing 
currents (which are: a. the sodium current (INa), b. the 
transient outward current (Ito) and c. the L (long-
lasting) -type calcium current also called ICaL)  and (2) 
the Outward currents (which are: a. the rapid 
component of the delayed rectifier potassium current 
(IKr), b. the slow component of the delayed rectifier 
potassium current (IKs), and c. the inward rectifier 
potassium current (IK1)) (20). In the general 
population, prolonged QTc is often predictive of life-
threatening arrhythmias, and adverse cardiovascular 
events and HIV/AIDS patients are not exempt from 
such risk (21). 
The higher prevalence of QTc prolongation 
observed among HIV patients compared to healthy 
controls in our study has been variously reported by 
other researchers (12, 22-25). Various reasons that 
account for this include autonomic dysfunction (25)  
and other established predisposing factors to QTc 
prolongation such as female sex, drugs and electrolyte 
abnormalities (26). 
Of the HIV patients in our study, the mean CD4 count 
was higher among patients who were on HAART than 
among those who were HAART-naïve. Our study 
found that QTc was the longest and the prevalence of 
QTc prolongation occurred most frequently in 
HAART-naïve patients followed by patients on 
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HAART with healthy control subjects having the 
lowest values of these parameters. Similar observations 
were reported by Ogunmola et al who suggested a 
relationship between CD4 count and QTc duration (22). 
This relationship is highlighted in our patients when 
their QTc duration and QTc prolongation prevalences 
were analysed with respect to the degree of 
immunosuppression as measured by the CD4 count. 
Patients with profound immunosuppression with CD4 
count <200 cells/mm
3
 had a longer QTc duration and 
higher prevalence of QTc prolongation than those with 
a higher CD4 count. This same trend was also reported 
by Gili et al (27) who found that a low CD4 count was 
associated with QTc prolongation independent of 
HAART. Nordin et al (10) also reported a similar trend 
in the association between CD4 count and QTc duration 
in their observation of an inverse correlation between 
CD4 count and QTc prolongation among HIV patients 
in their studied cohort. The relationship between the 
CD4 count and QTc prolongation may be mediated 
through the role of heightened inflammation and serum 
levels of inflammatory mediators which occur in 
patients with low CD4 count thereby predisposing them 
to QTc prolongation. In advanced HIV disease, 
depletion of the CD4 cells leads to the activation of 
CD8 killer T-cells which mediate persistent immune 
dysfunction and inflammation (28,29). 
The impact of inflammation on the occurrence of 
QTc prolongation has been elucidated by Lanzzerini et 
al (20). Inflammation is a cardinal feature of HIV 
infection and myocarditis, which occurs frequently in 
HIV (and which can be sub-clinical) is a known cause 
of QTc prolongation (30). The key inflammatory 
mediators of QTc prolongation identified by various 
workers include cytokines (particularly TNFα,  IL-6, 
IL-1β), which may affect the myocardium either 
directly, by modulating specific ion channels critically 
involved in action potential development, and 
indirectly, by increasing central nervous system 
sympathetic drive on the heart (31-33).    
The evaluation of the relationship between the use 
of HAART, and the prevalence of QTc prolongation 
has yielded different observations from different 
workers over time. Evaluating the possible effect of 
HAART on QTc is important because the number of 
patients accessing HAART in resource-poor settings 
such as ours has increased dramatically over the past 20 
years. Indeed, from 2001 to 2005, the number of 
persons receiving antiretroviral therapy in low-and 
middle-income countries increased 15- fold from 
240,000 to about 1.3 million (34), and a further 84% 
increase in access also occurred between 2010-2015 
(35). 
In assessing the impact of individual anti-
retroviral drug on QTc prolongation, our study 
observed that QTc prolongation in HIV patients was 
independent of all the individual anti-retroviral drugs 
taken by them. We assessed four nucleoside reverse 
transcriptase inhibitors (stavudine, lamivudine, 
zidovudine, emtricitabine), a nucleotide reverse 
transcriptase inhibitor (tenofovir) and two non-
nucleoside reverse transcriptase inhibitors (NNRTI) 
(nevirapine and efavirenz) in logistic regression model, 
and none of them was predictive of the occurrence of 
QTc prolongation. These are the commonest drugs used 
in combination for the care of HIV patients in the study 
centre. Our observation is similar to that of  Owens et al 
(36) and Chinello et al (37)  who also found that 
Nucleoside reverse transcriptase inhibitors and 
Nucleotide reverse transcriptase inhibitors were not 
associated with QTc prolongation. However, unlike our 
findings, these authors reported an association between 
efavirenz (an NNRTI) and nelfinavir (a PI). Only two 
of our patients were on a PI and were excluded from 
the regression analysis. The effect of PI on escalating 
cardiovascular risk factors such as dyslipidemia and 
coronary calcification has been reported by Meng et al 
(13).  In our centre, PIs are used as part of second-line 
HAART regimens when initial treatment with 
nucleoside reverse transcriptase inhibitors, nucleotide 
reverse transcriptase inhibitors and NNRTIs fail. 
Hence, very few of our patients were on them. Anson et 
al have demonstrated that QTc prolongation caused by 
some PIs; namely, amprenavir, indinavir, lopinavir, 
nelfinavir, ritonavir and saquinavir results from their 
suppression of the human ether-a-go-go–related gene 
(hERG) ion channel which mediates the repolarising 
inward potassium current,  IKr, which is one of the 
dominant  ionic currents involved in the generation of 
cardiac action potential (38).   The blockage of HERG 
channel and IKr induced by PIs, leads to a direct 
reduction in repolarisation reserve, prolongation of the 
duration of action potential and a concurrent rise in 
susceptibility to acquired long QT syndrome and 
torsade de pointes (38). 
Our study suggests that Nucleoside reverse 
transcriptase inhibitors and Nucleotide reverse 
transcriptase inhibitors used among HIV patients in our 
centre would not account for the QTc prolongation 
found among them compared to healthy controls. 
Possible pathogenetic factors may include well-known 
factors such as the effects of inflammation (discussed 
earlier) and oxidative stress on the myocardium (39). It 
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is possible to deduce that when patients commence 
HAART and their viral load drops, inflammatory 
processes mediated by the HIV subside, and these 
mechanisms which promote QTc prolongation are 
mitigated. Thus, the shorter QTc is observed among 
patients on HAART.  
Though our study may be limited by its cross-
sectional approach, it offers another perspective to an 
important scientific discussion. A prospective study 
will no doubt be needed to evaluate the relationship 
between HAART use and QTc prolongation, especially 
to examine the effect of PIs. 
In conclusion, QTc prolongation observed among 
our patients appears to be independent of their HAART 
use. We believe that it is important for physicians to 
consider the risk of QTc prolongation while managing 
HIV-infected persons particularly those yet to 
commence HAART. This will be useful as a strategy to 
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